Maravai LifeSciences Holdings, Inc. (MRVI) FY2026 YTD Q2 Statement of Cash Flows

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
Maravai LifeSciences Holdings, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Stock-based compensation expense → operating reconciliation: $16,948,000.00Amortization of intangible assets → operating reconciliation: $12,941,000.00Depreciation → operating reconciliation: $10,213,000.00Accounts payable → operating reconciliation: $4,362,000.00Loss on extinguishment of debt → operating reconciliation: $3,413,000.00Amortization of operating lease right-of-use assets → operating reconciliation: $3,231,000.00Prepaid expenses and other current assets → operating reconciliation: $662,000.00Impairment → operating reconciliation: $469,000.00Other → operating reconciliation: $201,000.00operating reconciliation → Net cash from operating activities: $12,657,000.00operating reconciliation → Net loss: $28,008,000.00operating reconciliation → Accounts receivable: $5,626,000.00operating reconciliation → Accrued expenses and other current liabilities: $3,521,000.00operating reconciliation → Other long-term liabilities: $1,893,000.00operating reconciliation → Inventory: $735,000.00investing reconciliation → Purchases of property and equipment: $4,807,000.00Net cash used in financing activities → financing reconciliation: $154,206,000.00Proceeds from borrowings of long-term debt → financing reconciliation: $150,000,000.00financing reconciliation → Principal repayments of long-term debt: $294,240,000.00financing reconciliation → Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of Class A common stock: $5,936,000.00financing reconciliation → Financing costs incurred for long-term debt: $3,575,000.00financing reconciliation → Other financing activities, net: $455,000.00Net cash used in investing activities → investing reconciliation: $4,807,000.00Exchange-rate effect → Cash sources and uses: $47,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $216,890,000.00Net cash from operating activities → Cash sources and uses: $12,657,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $70,581,000.00Cash sources and uses → Net cash used in investing activities: $4,807,000.00Cash sources and uses → Net cash used in financing activities: $154,206,000.00Net loss: -$28,008,000.00Net loss−$28.01 MDepreciation: $10,213,000.00Depreciation expense+$10.21 MAmortization of intangible assets: $12,941,000.00Intangible amortization+$12.94 MAmortization of operating lease right-of-use assets: $3,231,000.00Operating lease amortization+$3.23 MStock-based compensation expense: $16,948,000.00Stock-based compensation+$16.95 MLoss on extinguishment of debt: $3,413,000.00Debt extinguishment gain & loss+$3.41 MImpairment: $469,000.00Asset impairments+$469.00 KAcquisition related tax adjustment: $0.00Other: $201,000.00Other non-cash items+$201.00 KAccounts receivable: -$5,626,000.00Accounts receivable−$5.63 MInventory: -$735,000.00Inventories−$735.00 KPrepaid expenses and other current assets: $662,000.00Prepaid & other assets+$662.00 KAccounts payable: $4,362,000.00Accounts payable+$4.36 MAccrued expenses and other current liabilities: -$3,521,000.00Accrued liabilities−$3.52 MOther long-term liabilities: -$1,893,000.00Other noncurrent liabilities−$1.89 MNet cash from operating activities: $12,657,000.00Operating cash+$12.66 Moperating reconciliation: $52,440,000.00Proceeds from borrowings of long-term debt: $150,000,000.00Long-term debt issued+$150.00 MPrincipal repayments of long-term debt: -$294,240,000.00Long-term debt repaid−$294.24 MFinancing costs incurred for long-term debt: -$3,575,000.00Debt issuance costs−$3.58 MTaxes paid for shares withheld under employee equity plans, net of proceeds from issuance of Class A common stock: -$5,936,000.00Equity plan tax withholding, net−$5.94 MOther financing activities, net: -$455,000.00Other financing, net−$455.00 KNet cash used in financing activities: -$154,206,000.00. Cash required to fund net payments.Financing cash−$154.21 Mfinancing reconciliation: $304,206,000.00Cash paid for acquisitions of a business, net of cash acquired: $0.00Purchases of property and equipment: -$4,807,000.00PP&E purchases−$4.81 MNet cash used in investing activities: -$4,807,000.00. Cash required to fund net payments.Investing cash−$4.81 Minvesting reconciliation: $4,807,000.00Cash sources and uses: $229,594,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $216,890,000.00Beginning cash$216.89 MEnding cash: Cash, cash equivalents, and restricted cash: $70,581,000.00Ending cash$70.58 MExchange-rate effect: $47,000.00FX effect+$47.00 KCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsNet loss −$28.01M + net operating adjustments $40.67M = operating cash +$12.66MFree cash flow$7.85 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$146.31 MEnding cash − beginning cash
Chart details

Maravai LifeSciences Holdings, Inc. cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
216,890,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
12,657,000 US dollars. Net cash provided.
Net loss
negative 28,008,000 US dollars
Depreciation
10,213,000 US dollars
Amortization of intangible assets
12,941,000 US dollars
Amortization of operating lease right-of-use assets
3,231,000 US dollars
Stock-based compensation expense
16,948,000 US dollars
Loss on extinguishment of debt
3,413,000 US dollars
Impairment
469,000 US dollars
Acquisition related tax adjustment
0 US dollars
Other
201,000 US dollars
Accounts receivable
negative 5,626,000 US dollars
Inventory
negative 735,000 US dollars
Prepaid expenses and other current assets
662,000 US dollars
Accounts payable
4,362,000 US dollars
Accrued expenses and other current liabilities
negative 3,521,000 US dollars
Other long-term liabilities
negative 1,893,000 US dollars
Investing activities
negative 4,807,000 US dollars. Net cash used.
Cash paid for acquisitions of a business, net of cash acquired
0 US dollars
Purchases of property and equipment
negative 4,807,000 US dollars
Financing activities
negative 154,206,000 US dollars. Net cash used.
Proceeds from borrowings of long-term debt
150,000,000 US dollars
Principal repayments of long-term debt
negative 294,240,000 US dollars
Financing costs incurred for long-term debt
negative 3,575,000 US dollars
Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of Class A common stock
negative 5,936,000 US dollars
Other financing activities, net
negative 455,000 US dollars
Operating adjustment reconciliation
52,440,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
304,206,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
4,807,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
47,000 US dollars
Ending cash on Jun 30, 2026
70,581,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
229,594,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 146,309,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
12,657,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
4,807,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
7,850,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$28.01M + net operating adjustments $40.67M = operating cash +$12.66M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 12,657,000 US dollars minus 4,807,000 US dollars equals 7,850,000 US dollars.
Maravai LifeSciences Holdings, Inc. (MRVI) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!